Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.55 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.55 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858019 | 0.86 | GAA (0.66) | GAAKDM4EL3MBTL1ALDH1A1TSHR | |
| SCHEMBL11786623 | 0.85 | GAA (0.65) | GAAKDM4EL3MBTL1ALDH1A1TSHR | |
| SCHEMBL30107521 | 0.84 | GAA (0.64) | GAAKDM4EL3MBTL1ALDH1A1TSHR | |
| SCHEMBL6222692 | 0.84 | GAA (0.64) | GAAKDM4EL3MBTL1ALDH1A1TSHR | |
| SCHEMBL11789215 | 0.83 | GAA (0.63) | GAAKDM4EL3MBTL1ALDH1A1TSHR | |
| SCHEMBL1343798 | 0.83 | KDM4E (0.63) | GAAKDM4EL3MBTL1ALDH1A1TSHR | |
| SCHEMBL29769835 | 0.82 | L3MBTL1 (0.63) | GAAKDM4EL3MBTL1ALDH1A1TSHR | |
| SCHEMBL1084996 | 0.82 | L3MBTL1 (0.63) | GAAKDM4EL3MBTL1ALDH1A1TSHR | |
| SCHEMBL20456029 | 0.82 | GAA (0.65) | GAAKDM4EL3MBTL1ALDH1A1TSHR | |
| SCHEMBL13210703 | 0.81 | RAB9A (0.65) | GAAKDM4EL3MBTL1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024124279-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CERTA THERAPEUTICS PTY LTD (AU) | 2024-06-20 | — | — | WO | disclosed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| EP-4013508-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | Bayer Aktiengesellschaft (DE) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021077102-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
| WO-2015088564-A1 | P2X4 RECEPTOR MODULATING COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015088565-A1 | P2X4 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| EP-1722796-A4 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007117289-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-18 | — | — | WO | disclosed |
| CN-101014343-A | Tetracyclic lactam derivatives and uses thereof | INOTEK PHARMACEUTICALS CORP (US) | 2007-08-08 | — | — | CN | disclosed |
| EP-1722796-A2 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | Inotek Pharmaceuticals Corporation (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005082079-A2 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| US-4578389-A | HYPOTENSIVE AGENTS | LUDWIG HEUMANN & CO. GMBH (DE) | 1986-03-25 | — | — | US | disclosed |
| US-4578389-A | HYPOTENSIVE AGENTS | LUDWIG HEUMANN & CO. GMBH (DE) | 1986-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | GAA 3740/4885KDM4E 1364/4885L3MBTL1 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.